190 research outputs found
Pure small cell carcinoma of the prostate: A rare tumor.
No full textPure small cell carcinoma of the prostate is a rare and aggressive neoplasm, with only few cases described in literature and poor prognosis: mean survival is 5 months. We report the case of a patient with this disease, with special attention to the evolution of neuroendocrine markers as Chromogranine A and neuron-specific enolase during the progression of the tumor, evaluating their possible role in staging and follow up
Androgen levels and high grade prostate cancer: free to total testosterone ratio analysis
No full textUnderstanding biochemical recurrence after radical prostatectomy: trust biology, not a number
No full textLa composizione negoziata della crisi
No full textIl lavoro analizza il nuovo procedimento di composizione negoziata della crisi in riferimento all'impresa agricol
Prebiopsy 68Ga-PSMA PET imaging. can we improve the current diagnostic pathway for prostate cancer?
No full textProstate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly expanding in the diagnostic pathway of prostate cancer (PCa). 68Ga-PSMA PET/CT, the most studied PSMA radiotracer, is currently recommended in case of biochemical recurrence after radical prostatectomy [1]. It is also being progressively used before surgery [2] for primary staging of highrisk prostate cancer, particularly when conventional imaging is negative with high clinical suspicion of metastatic disease
Editorial. new horizons in robotic platforms
No full textAt the beginning of the 21st century, the first Intuitive Surgical Da Vinci system was introduced. Historically, the AESOP and ZEUS systems were the first robots adopted in general surgery before Intuitive and American Computer Motion merged into a single company. By 2023, over 7500 robotic platforms have been installed, with over 11 million surgeries performed worldwide. The success of the robotic platform relies on the magnification, 3D imaging, motion scaling, tremor filtration, dexterity and quick learning curve of the machine. After many years of monopoly by Intuitive, several companies have proposed new robotic platforms that may challenge the Da Vinci system [1]
The Future of Medical Devices in Europe Is at Stake: Concerns over the Implementation of the Medical Devices Regulation 2017/745
No full textIn May 2024, all medical devices in Europe will require to comply with the new Medical Device Regulation 2017/745, including those we have been using for years. Currently, there are major delays and problems associated with this new certification. As clinicians, we express our serious concerns regarding whether the system will be ready on time to ensure that all the medical devices that we use will be available for patient care.status: Publishe
Risk factor assessment in high-risk, bacillus Calmette–Guérin-treated, non-muscle-invasive bladder cancer
No full textSerge Holz,* Simone Albisinni,* Jacques Gilsoul, Michel Pirson, Véronique Duthie, Thierry Quackels, Marc Vanden Bossche, Thierry Roumeguère Department of Urology, Erasme Hospital, Université libre de Bruxelles, Belgium *These authors contributed equally to this work Objective: To assess the risk factors associated with recurrence, progression and survival in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with bacillus Calmette–Guérin (BCG) and validate the European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) scores.Patients and methods: We retrospectively analyzed all BCG-treated NMIBC patients from 1998 to 2012. Multiple variables were tested as risk factors for recurrence-free survival and progression-free survival (PFS). Variables included age, sex, grade, stage, tumor size, number of tumors, carcinoma in situ (CIS), recurrence status, BCG strain used, smoking status, use of re-staging transurethral resection and use of single immediate postoperative instillation. We also tested the accuracy of EORTC and CUETO scores in predicting recurrence and progression.Results: Overall, 123 patients were analyzed. Median (interquartile range) follow-up was 49 months. The 5-year overall survival, cancer-specific survival, recurrence-free survival and PFS were 75.0%, 89.3%, 59.4% and 79.2%, respectively. On univariate analysis, multiple tumors (≥3), concomitant CIS and smoking influenced recurrence. Regarding progression, multiple tumors, concomitant CIS and Connaught strain (vs Tice) negatively influenced PFS on univariate and multivariate analyses were independent prognostic factors. CUETO scores were accurate, with a slight overestimation, while EORTC score was not predictive of recurrence or progression.Conclusion: In this study, CIS and tumor multiplicity were unfavorable predictors of recurrence and progression in patients with NMIBC receiving BCG. CUETO model was superior to EORTC risk tables in predicting recurrence and progression in our BCG-treated patient population. Nonetheless, both scores overestimated recurrence and progression rates. Prospective trials are needed to validate our findings. Keywords: BCG, bladder cancer, progression, recurrenc
- …
